Keywords: ph, iii, ofatumumab, trial, nhl, completes, recruitment

Ph III ofatumumab trial in NHL completes recruitment

Article | 20 October 2008

Print This

Danish biotechnology firm Genmab AS has completed recruitment of patients in the pivotal Phase III trial of ofatumumab (HuMax-CD20) in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in